On the sidelines of the inaugural annual global AlUla Conference for Emerging Market Economies in Al Ula, Saudi Arabia (February 16-17), Saudi Arabia's Finance Ministry and the International Monetary ...

The Ontario Securities Commission (OSC) announced today it will participate in a multi-jurisdictional settlement, along with other provincial and U.S. state securities regulators, with GS Partners and ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 10% in early trading, largely because of weaker ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...

and heads of other International Financial Institutions and the Arab Coordination Group. Following the meeting, Kristalina Georgieva, Managing Director of the IMF, and Mohammed Aljadaan, Finance ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Arne Dedert / Picture Alliance / Getty Images Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of estimates. Revenue and adjusted earnings ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of its HPV vaccine, Gardasil, to reach $11 billion by 2030. The result ...